Brief: Neurosense Therapeutics Says Planning For Phase 3 Clinical Study In US And Europe

Neurosense Therapeutics

01/07/2024 14:42

July 1 (Reuters) - Neurosense Therapeutics Ltd  NRSN.O :
    * NEUROSENSE DEMONSTRATES STATISTICALLY SIGNIFICANT EFFICACY
AND
SURVIVAL BENEFITS IN PEOPLE LIVING WITH ALS: THE PROMISING
RESULTS FROM THE 12-MONTH PARADIGM STUDY HIGHLIGHT PRIMEC'S
POTENTIAL AS A DISEASE MODIFYING DRUG
    * NEUROSENSE THERAPEUTICS LTD -NEUROSENSE PLANNING FOR PHASE
3
CLINICAL STUDY IN U.S. AND EUROPE
    * NEUROSENSE THERAPEUTICS: DISEASE PROGRESSION SLOWED BY 36%
IN
PARTICIPANTS WHO RECEIVED PRIMEC FOR 12 MONTHS VERSUS THOSE WHO
INITIALLY RECEIVED PLACEBO
    * NEUROSENSE THERAPEUTICS LTD -CONSISTENT DATA ACROSS
MULTIPLE
ENDPOINTS UNDERSCORE POTENTIAL OF PRIMEC TO REDEFINE ALS
TREATMENT PARADIGM

Source text for Eikon:  ID:nPn1bhmXka 
Further company coverage:  NRSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))